MREO vs. SAGE

Last updated Jun 3, 2026

MREO (Mereo BioPharma Group plc) and SAGE (Sage Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.24 correlation, their price movements are largely independent.

Performance

MREO vs. SAGE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mereo BioPharma Group plc (MREO) and Sage Therapeutics, Inc. (SAGE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

MREO

• 1D: 10.27%
• 1M: 30.54%
• YTD: -18.55%
• 6M: -80.61%
• 1Y: -86.69%
• 3Y*: -31.59%
• 5Y*: -37.64%
• 10Y*: —

SAGE

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MREO vs. SAGE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MREO Mereo BioPharma Group plc	-18.55%	-88.09%	51.52%	208.00%	-53.12%	-55.31%	9.15%	-49.54%
SAGE Sage Therapeutics, Inc.	0.00%	59.85%	-74.94%	-43.18%	-10.34%	-50.83%	19.84%	-56.10%

Correlation

The correlation between MREO and SAGE is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.01
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (All Time) Calculated using the full available price history since Apr 25, 2019	0.24

Over the past year, the correlation between MREO and SAGE has dropped to 0.01 - well below their long-term average of 0.24, suggesting their price drivers have been diverging.

Fundamentals

Market Cap MREO : $54.43M SAGE : $543.46M
EPS MREO : -$0.22 SAGE : -$4.81
PS Ratio MREO : 108.55 SAGE : 7.72
PB Ratio MREO : 1.60 SAGE : 1.47
Total Revenue (TTM) MREO : $500.00K SAGE : $70.41M
Gross Profit (TTM) MREO : $366.00K SAGE : $63.04M
EBITDA (TTM) MREO : -$39.61M SAGE : -$302.71M

Return for Risk

MREO vs. SAGE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MREO

MREO Risk / Return Rank: 14
MREO Sharpe Ratio Rank: 13
MREO Sortino Ratio Rank: 24
MREO Omega Ratio Rank: 21
MREO Calmar Ratio Rank: 5
MREO Martin Ratio Rank: 9

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MREO vs. SAGE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mereo BioPharma Group plc (MREO) and Sage Therapeutics, Inc. (SAGE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MREO	SAGE	Difference
Sharpe ratio Return per unit of total volatility	-0.65	—	—
Sortino ratio Return per unit of downside risk	-0.25	—	—
Omega ratio Gain probability vs. loss probability	0.95	—	—
Calmar ratio Return relative to maximum drawdown	-0.92	—	—
Martin ratio Return relative to average drawdown	-1.35	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	MREO	SAGE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.65	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	—	—

Drawdowns

Drawdown Indicators

	MREO	SAGE	Difference
Max Drawdown Largest peak-to-trough decline	-96.35%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-91.93%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-95.13%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-95.13%	—	—
Current Drawdown Current decline from peak	-94.78%	—	—
Average Drawdown Average peak-to-trough decline	-65.88%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	62.41%	—	—

Volatility

Volatility by Period

	MREO	SAGE	Difference
Volatility (1M) Calculated over the trailing 1-month period	37.15%	—	—
Volatility (6M) Calculated over the trailing 6-month period	224.43%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	135.47%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	100.56%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	113.69%	—	—

Dividends

MREO vs. SAGE - Dividend Comparison

Neither MREO nor SAGE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MREO and SAGE in my portfolio?

MREO and SAGE have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.